The day that Athena Countouriotis, then the CEO of Turning Point Therapeutics, announced that the San Diego biotech was acquired by Bristol Myers Squibb for $4.1 billion, people were already asking her: what’s next? Less than a year later, in 2022 she partnered with Turning Point’s chief medical officer, Mohammad Hirmand to launch Avenzo Therapeutics, a clinical stage oncology company.
San Diego’s newest biotech company hopes to accelerate the research and discovery of viable medicines through Mirador360, its proprietary precision development engine that leverages genetic information and data science. “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said McKenna, chairman and CEO of Mirador in the March 21 announcement.